As expected, the inhibitor Kpt185, which targets XPO1, significantly reduced the proliferation and survival of HCC cells, with an IC50 of 2.12 μM and 3.7 μM (Figure 5G), suggesting XPO1 as a target for C1 subtype of HCC. Here, XPO1 is linked to hepatocellular carcinoma.